Financial Statements Auditors Reports on the Financial Statements and on Internal Control overFinancial Reporting Sarbanes-Oxley Act Section 404 The report set out below is provided in Exchange Commission.
Those reports are KPMG Audit Plc has also reported separately compliance with International Standards on unqualified and include opinions on the on the Company Financial Statements of Auditing UK and Ireland.
KPMG Audit Plc Group Financial Statements and on AstraZeneca PLC and on the information has also issued reports in accordance with theeffectiveness of internal control over inthe Directors Remuneration Report standards of the Public Company Accounting financial reporting as at 31 December 2013 thatis described as having been audited.
Oversight Board in the US, which will be Sarbanes-Oxley Act Section 404.
The This audit report is set out on page 187. included in the Annual Report on Form 20-F Directors statement on internal control over to be filed with the US Securities and financial reporting is set out on page 127.
Independent Auditors Report to the Members of AstraZeneca PLC only Opinions and conclusions arising have been properly prepared in the Group, in addition to complying with its from our audit accordance with International Financial legal obligation to apply IFRSs as adopted 1.
Our opinion on the Group Financial Reporting Standards IFRSs as adopted by the EU, has also applied IFRSsas issued Statements is unmodified by the European Union EU : and by the IASB.
We have audited the Group Financial have been prepared in accordance with In our opinion, the Group Financial Statements of AstraZeneca PLC for the the requirements of the Companies Act Statements comply with IFRSs as issued year ended 31 December 2013 set out 2006 and Article 4 of the IAS Regulation.
In our opinion the Group Financial Statements: 2.
Separate opinion in relation to 3.
Our assessment of risks of IFRSsas issued by the International materialmisstatement give a true and fair view of the state of the Accounting Standards Board IASB In arriving at our audit opinion above on the Groups affairs as at 31 December 2013 As explained in the Group Accounting Financial Statements the risks of material and of its profit for the year then ended: Policies section of the Group Financial misstatement that had the greatest effect Statements set out on pages 136 to 140, on our audit were as follows.
Revenue recognition $25,711m Refer to page 100 Audit Committee Report, page 137 accounting policy, page 141 and 147 financial disclosures and page 83 financial risk management The risk Our response Revenue recognition is one of the key Our principal audit procedures included: testing the Groups controls surrounding revenue judgemental areas for our audit, particularly recognition and key manual and systems-based controls in the order-to-cash transaction in respect of estimates made for rebates, cycle, including reconciliations between sales systems and the general ledger: assessing chargebacks and returns under contractual whether appropriate revenue recognition policies are applied through comparison with and regulatory requirements in the US which accounting standards: and performing testing over revenue at significant components, are deducted in arriving at revenue.
which included analysis of product sales year on year, corroborating movements compared with expectations and inspection of contracts with customers.
Our audit work in respect of the accrual for US rebates, chargebacks and returns involved testing key controls including the Groups review of claims, credits and system accrual rates.
In addition, we considered the accuracy and integrity of the accrual calculation, corroborated inputs and key assumptions, both to internal and independent sources, and considered the historical accuracy of the accrual.
We also assessed the adequacy of the Groups disclosures of its revenue recognition policy and other related disclosures.
128 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information Carrying value of intangible assets $16,047m Refer to page 100 Audit Committee Report, page 140 accounting policy, page 150 financial disclosures and page 85 financial risk management.
The risk Our response The Group has significant intangible assets In this area our principal audit procedures included evaluating the Groups assumptions arising from the acquisition of products both used in assessing the recoverability of intangible assets, in particular, revenue and cashflow launched and in development.
Recoverability projections, useful life and discount rates.
We also performed sensitivity analysis over of these assets is based on forecasting and individual intangible asset models where there was a higher risk of impairment.
For products discounting future cash flows, which are in development, a key assumption is the probability of obtaining the necessary clinical and inherently judgemental.
For products in regulatory approvals.
Our procedures around such products in development included development the main risk is successful critically assessing the reasonableness of the Groups assumptions through consideration trial results and obtaining required regulatory of trial readouts, regulatory announcements and the Groups internal governance and approvals.
For launched products, the key approval process.
We also interviewed a range of key Research and Development personnel risk is the ability to successfully commercialise and compared assumptions with industry practice.
For launched products we challenged the individual product concerned.
key assumptions including the size of the therapeutic area market, the products projected share and expected pricing and associated costs.
Our procedures also included holding discussions with relevant management personnel, sensitivity analysis based on our experience in the sector and retrospective assessment of the accuracy of the Groups projections.
We also assessed the adequacy of the Groups disclosures in respect of the carrying value of intangible assets.
Litigation and contingent liabilities provisions of $59m Refer to page 101 Audit Committee Report, page 139 accounting policy, page 176 financial disclosures and page 86 financial risk management.
The risk Our response In the normal course of business, contingent Having made enquires of the Directors to obtain their view on the status of significant legal liabilities may arise from product-specific and matters, our principal audit procedures included: assessment of correspondence with the general legal proceedings, from guarantees, Groups external counsel on all significant legal cases and discussions with external counsel government investigations or from where necessary.
In addition we obtained formal confirmations from the Groups external environmental liabilities connected with the counsel for all significant litigation, used our own forensic and compliance specialists to Groups current or former sites.
The amounts assess the Groups compliance logs and reports to identify actual and potential noninvolved are potentially material and the compliance with laws and regulations, both those specific to the Groups business and application of accounting standards to those relating to the conduct of business generally, analysed correspondence with regulators determine the amount, if any, to be provided and monitored external sources.
We also assessed whether the Groups disclosures detailing as a liability, is inherently subjective.
significant legal proceedings adequately disclose the potential liabilities of the Group.
Tax provisioning $2,576m Refer to page 101 Audit Committee Report, page 138 accounting policy, page 183 financial disclosures and page 87 financial risk management.
The risk Our response Due to the Group operating in a number of In this area our principal audit procedures included: assessment of correspondence with different tax jurisdictions and the complexities the relevant tax authorities, and the use of our own local and international tax specialists of transfer pricing and other international tax to analyse and challenge the assumptions used to determine tax provisions based on our legislation, accruals for tax contingencies knowledge and experiences of the application of the relevant legislation by authorities and require the Directors to make judgements courts.
We also assessed the adequacy of the Groups disclosures in respect of tax and and estimates in relation to tax issues uncertain tax positions.
Post-retirement benefits $2,261m Refer to page 101 Audit Committee Report, page 138 accounting policy, page 159 financial disclosures and page 86 financial risk management.
The risk Our response Significant estimates are made in valuing Our principal audit procedures included the challenge of key assumptions, being the the Groups post-retirement defined benefit discount rate, inflation rate and mortality life expectancy supporting the valuation of the plans.
Small changes in assumptions and Groups retirement benefit obligations, with the support of our own actuarial specialists.
estimates used to value the Groups net This involved a comparison of these key assumptions used against externally derived data.
pension deficit would have a significant We obtained third party assurance reports on controls over the valuation of pension assets effect on the Groups financial position.
held by key custodians and compared asset values to third party confirmations.
We also assessed the adequacy of the Groups disclosures in respect of post-retirement benefits.
AstraZeneca Annual Report and Form 20-F Information 2013 129 Financial Statements |Auditors Reports 4.
Our application of materiality and Materiality of the Group FinancialStatements anoverview of the scope of our audit The materiality for the Group Financial profit before tax plus Statements as a whole was set at $248m.
significant impairment Materiality This has been determined with reference to $4,979m $248m Whole financial a benchmark of Group profit before taxation, statements materiality which we consider to be one of the principal considerations for members of the Company in assessing the financial performance of the Group.
Materiality represents 7.6% of Group profit before tax and 5.0% of Group profit before tax $188m Range of materiality at adjusted for this years significant intangible seven key components asset impairment as disclosed in Note 9.
$8m-$188m We agreed with the Audit Committee to $12m Misstatements reported report to it all corrected and uncorrected to the Audit Committee misstatements we identified through our audit with a value in excess of $12m, in addition to other audit misstatements below that threshold The audits undertaken for Group reporting the key locations in the following countries that we believe warranted reporting purposes at the key reporting components to discuss key risks and audit strategy: on qualitative grounds.
of the Group were all performed to lower theUK, the US, Sweden and Japan.
Video Audits for Group reporting purposes were materiality levels set individually for each and telephone conference meetings were performed by component auditors at seven component which ranged from $8m up also held with the auditors at these locations key reporting components in the following to$188m.
and all other key reporting components countries: the UK, the US, Sweden, China, that were not physically visited.
In addition, Detailed audit instructions were sent to all Japan, Germany and France.
In addition, detailed specified procedures instructions the auditors in key components and shared specified audit procedures predominantly were sent to all audit teams for work to be service centres.
These instructions covered the testing of transaction processing carried out at the shared service centre the significant audit areas that should be andreview controls for Group reporting locations.
Reporting by exception is also covered by these audits which included purposes were performed at the Groups obtained from the majority of the other the relevant risks of material misstatement shared service centres both in-house and subsidiaries where a local statutory audit detailed above and set out the information outsourced in the UK, Malaysia, Romania isrequired, but are not included in scope required to be reported back to the Group and India.
The coverage achieved by for audit or specified audit procedures audit team.
The Group audit team visited theseGroup procedures is shown in the Group reporting.
Scoping and coverage Group revenue Components absolute pro ts losses Group total assets Key Components 66% Key Components 66% Key Components 88% Shared Service Centre 22% Shared Service Centre 23% Shared Service Centre 6% Not covered by Audit Work Not covered by Audit Work Not covered by Audit Work 130 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information 5.
Our opinion on the other matter Under the Listing Rules we are required prescribed by the Companies Act 2006 toreview: is unmodified the Directors statement, set out on In our opinion the information given in the page136, in relation to going concern: and Strategic Report and the Directors Report the part of the Corporate Governance for the financial year for which the Financial Report on pages 88 to 97 relating to the Statements are prepared is consistent with companys compliance with the nine the Group Financial Statements.
provisions of the 2010 UK Corporate 6.
We have nothing to report in respect Governance Code specified for our review.
of the matters on which we are required We have nothing to report in respect of the to report by exception above responsibilities.
Under ISAs UK and Ireland we are required to report to you if, based on the knowledge 7.
Other matter we have reported we acquired during our audit, we have separately on the Parent Company identified other information in this Annual Financial Statements Report that contains a material inconsistency We have reported separately on the with either that knowledge or the Financial ParentCompany Financial Statements Statements, a material misstatement of ofAstraZeneca PLC for the year ended fact, or that is otherwise misleading.
31December 2013 and on the information in the Directors Remuneration Report that In particular, we are required to report to is described as having been audited.
you if: Scope of report and responsibilities we have identified material inconsistencies As explained more fully in the Directors between the knowledge we acquired Responsibilities Statement set out on page during our audit and the Directors 127, the Directors are responsible for the statement that they consider that the preparation of the Financial Statements Annual Report and Financial Statements and for being satisfied that they give a true taken as a whole are fair, balanced and fair view.
A description of the scope of andunderstandable and provides the an audit of Financial Statements is provided information necessary for shareholders on the Financial Reporting Councils website to assess the Groups performance, at www.
business model and strategy: or This report is made solely to the Companys the Audit Committee Report does members as a body and is subject to notappropriately address matters important explanations and disclaimers communicated by us to the regarding our responsibilities, published AuditCommittee.
com uk Under the Companies Act 2006 we are auditscopeukco2013b, which are required to report to you if, in our opinion: incorporated into this report as if set out infull and should be read to provide an certain disclosures of Directors understanding of the purpose of this report, remuneration specified by law are the work we have undertaken and the basis notmade: or of our opinions.
we have not received all the information and explanations we require for our audit.
Antony Cates Senior Statutory Auditor for and on behalf of KPMG Audit Plc, Statutory Auditor Chartered Accountants 15 Canada Square London E14 5GL 6 February 2014 AstraZeneca Annual Report and Form 20-F Information 2013 131 Financial Statements Consolidated Statement of Comprehensive Income for the year ended 31 December 2012 2011 2013 Restated Restated Notes $m $m $m Revenue 1 25,711 27,973 33,591 Cost of sales 5,261 5,393 6,026 Gross profit 20,450 22,580 27,565 Distribution costs 306 320 346 Research and development expense 2 4,821 5,243 5,523 Selling, general and administrative costs 2 12,206 9,839 11,161 Profit on disposal of subsidiary 2, 22 1,483 Other operating income and expense 2 595 970 777 Operating profit 2 3,712 8,148 12,795 Finance income 3 50 42 50 Finance expense 3 495 544 562 Profit before tax 3,267 7,646 12,283 Taxation 4 696 1,376 2,333 Profit for the period 2,571 6,270 9,950 Other comprehensive income: Items that will not be reclassified to profit or loss: Remeasurement of the defined benefit liability 18 8 13 657 Tax on items that will not be reclassified to profit or loss 4 82 65 164 74 78 493 Items that may be reclassified subsequently to profit or loss: Foreign exchange arising on consolidation 166 106 60 Foreign exchange differences on borrowings designated in net investment hedges 58 46 24 Fair value movements on derivatives designated in net investment hedges 111 76 Amortisation of loss on cash flow hedge 1 1 2 Net available for sale gains taken to equity 69 72 31 Tax on items that may be reclassified subsequently to profit or loss 4 4 4 16 39 213 13 Other comprehensive income for the period, net of tax 113 135 480 Total comprehensive income for the period 2,458 6,405 9,470 Profit attributable to: Owners of the Parent 2,556 6,240 9,917 Non-controlling interests 15 30 33 Total comprehensive income attributable to: Owners of the Parent 2,470 6,395 9,428 Non-controlling interests 12 10 42 Basic earnings per $0.25 Ordinary Share 5 $2.04 $4.95 $7.29 Diluted earnings per $0.25 Ordinary Share 5 $2.04 $4.94 $7.25 Weighted average number of Ordinary Shares in issue millions 5 1,252 1,261 1,361 Diluted weighted average number of Ordinary Shares in issue millions 5 1,254 1,264 1,367 Dividends declared and paid in the period 21 3,499 3,619 3,752 Restatement on adoption of IAS 19 2011, as detailed in Group Accounting Policies.
All activities were in respect of continuing operations.
$m means millions of US dollars.
132 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information Consolidated Statement of Financial Position at 31 December 2012 2011 2013 Restated Restated Notes $m $m $m Assets Non-current assets Property, plant and equipment 7 5,818 6,089 6,425 Goodwill 8 9,981 9,898 9,862 Intangible assets 9 16,047 16,448 10,980 Derivative financial instruments 15 365 389 342 Other investments 10 281 199 201 Other receivables 12 1,867 352 Deferred tax assets 4 1,205 1,111 1,514 35,564 34,486 29,324 Current assets Inventories 11 1,909 2,061 1,852 Trade and other receivables 12 7,879 7,629 8,754 Other investments 10 796 823 4,248 Derivative financial instruments 15 40 31 25 Income tax receivable 494 803 1,056 Cash and cash equivalents 13 9,217 7,701 7,571 20,335 19,048 23,506 Total assets 55,899 53,534 52,830 Liabilities Current liabilities Interest-bearing loans and borrowings 14 1,788 901 1,990 Trade and other payables 16 10,362 9,221 8,975 Derivative financial instruments 15 2 3 9 Provisions 17 823 916 1,388 Income tax payable 3,076 2,862 3,390 16,051 13,903 15,752 Non-current liabilities Interest-bearing loans and borrowings 14 8,588 9,409 7,338 Derivative financial instruments 15 1 Deferred tax liabilities 4 2,827 2,576 2,735 Retirement benefit obligations 18 2,261 2,271 2,680 Provisions 17 566 428 474 Other payables 16 2,352 1,001 385 16,595 15,685 13,612 Total liabilities 32,646 29,588 29,364 Net assets 23,253 23,946 23,466 Equity Capital and reserves attributable to equity holders of the Company Share capital 20 315 312 323 Share premium account 3,983 3,504 3,078 Capital redemption reserve 153 153 139 Merger reserve 433 433 433 Other reserves 19 1,380 1,374 1,379 Retained earnings 19 16,960 17,955 17,888 23,224 23,731 23,240 Non-controlling interests 29 215 226 Total equity 23,253 23,946 23,466 Restatement on adoption of IAS 19 2011, as detailed in Group Accounting Policies.
The Financial Statements from page 132 to 186 were approved by the Board on 6 February 2014 and were signed on its behalf by Pascal Soriot Marc Dunoyer Director Director AstraZeneca Annual Report and Form 20-F Information 2013 133 Financial Statements Consolidated Statement of Changes in Equity for the year ended 31 December Share Capital Total NonShare premium redemption Merger Other Retained attributable controlling Total capital account reserve reserve reserves earnings to owners interests equity $m $m $m $m $m $m $m $m $m At 1 January 2011 as previously stated 352 2,672 107 433 1,377 18,272 23,213 197 23,410 Restatement 6 6 6 At 1 January 2011 352 2,672 107 433 1,377 18,266 23,207 197 23,404 Profit for the period 9,917 9,917 33 9,950 Other comprehensive income 489 489 9 480 1 Transfer to other reserves 2 2 Transactions with owners Dividends 3,752 3,752 3,752 Issue of Ordinary Shares 3 406 409 409 Repurchase of Ordinary Shares 32 32 6,015 6,015 6,015 Share-based payments 37 37 37 Transfer from non-controlling interests to payables 9 9 Dividend paid by subsidiary to non-controlling interests 4 4 Net movement 29 406 32 2 378 33 29 62 At 31 December 2011 323 3,078 139 433 1,379 17,888 23,240 226 23,466 Profit for the period 6,240 6,240 30 6,270 Other comprehensive income 155 155 20 135 1 Transfer to other reserves 5 5 Transactions with owners Dividends 3,619 3,619 3,619 Issue of Ordinary Shares 3 426 429 429 Repurchase of Ordinary Shares 14 14 2,635 2,635 2,635 Share-based payments 79 79 79 Transfer from non-controlling interests to payables 10 10 Dividend paid by subsidiary to non-controlling interests 11 11 Net movement 11 426 14 5 67 491 11 480 At 31 December 2012 312 3,504 153 433 1,374 17,955 23,731 215 23,946 Profit for the period 2,556 2,556 15 2,571 Other comprehensive income 86 86 27 113 1 Transfer to other reserves 6 6 Transactions with owners Dividends 3,499 3,499 3,499 Issue of Ordinary Shares 3 479 482 482 Share-based payments 57 57 57 Transfer from non-controlling interests to payables 6 6 Dividend paid by subsidiary to non-controlling interests 3 3 2 Net acquisition of non-controlling interests 97 97 165 68 Net movement 3 479 6 995 507 186 693 At 31 December 2013 315 3,983 153 433 1,380 16,960 23,224 29 23,253 Restatement on adoption of IAS 19 2011, as detailed in Group Accounting Policies.
1 Amounts charged or credited to other reserves relate to exchange adjustments arising on goodwill.
2 Net acquisition of non-controlling interests in 2013 includes acquisitions with cash payments of $110m due in 2014 and disposals with cash of $42m received in the year.
134 AstraZeneca Annual Report and Form 20-F Information 2013 Strategic Report Corporate Governance Financial Statements Additional Information Consolidated Statement of Cash Flows for the year ended 31 December 2012 2011 2013 Restated Restated Notes $m $m $m Cash flows from operating activities Profit before tax 3,267 7,646 12,283 Finance income and expense 3 445 502 512 Depreciation, amortisation and impairment 4,583 2,518 2,550 Increase decrease in trade and other receivables 383 755 1,108 Decrease increase in inventories 135 150 256 Increase decrease in trade and other payables and provisions 414 1,311 467 Profit on disposal of subsidiary 22 1,483 Non-cash and other movements 258 424 597 Cash generated from operations 8,719 9,536 12,368 Interest paid 475 545 548 Tax paid 844 2,043 3,999 Net cash inflow from operating activities 7,400 6,948 7,821 Cash flows from investing activities Acquisitions of business operations 22 1,158 1,187 Movement in short-term investments and fixed deposits 130 3,619 2,743 Purchase of property, plant and equipment 742 672 839 Disposal of property, plant and equipment 69 199 102 Purchase of intangible assets 1,316 3,947 458 Disposal of intangible assets 35 Purchase of non-current asset investments 91 46 11 Disposal of non-current asset investments 38 43 Net cash received on disposal of subsidiary 22 1,772 Dividends received 7 Interest received 114 145 171 Payments made by subsidiaries to non-controlling interests 10 20 16 Payments received by subsidiaries from non-controlling interests 42 Net cash outflow from investing activities 2,889 1,859 2,022 Net cash inflow before financing activities 4,511 5,089 5,799 Cash flows from financing activities Proceeds from issue of share capital 482 429 409 Repurchase of shares 2,635 6,015 Repayment of obligations under finance leases 27 17 Issue of loans 1,980 Repayment of loans 1,750 Dividends paid 3,461 3,665 3,764 Hedge contracts relating to dividend payments 36 48 3 Movement in short-term borrowings 5 687 46 Net cash outflow from financing activities 3,047 4,923 9,321 Net increase decrease in cash and cash equivalents in the period 1,464 166 3,522 Cash and cash equivalents at the beginning of the period 7,596 7,434 10,981 Exchange rate effects 65 4 25 Cash and cash equivalents at the end of the period 13 8,995 7,596 7,434 Restatement on adoption of IAS 19 2011, as detailed in Group Accounting Policies.
AstraZeneca Annual Report and Form 20-F Information 2013 135
